Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 6, 2025
Product Development

Telix’s end-to-end radiopharma ambitions

With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Apr 22, 2019
Distillery Therapeutics

Inhibiting the LLGL2-SLC7A5-YKT6 complex for breast cancer

BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

New advances in PD-1 combinations, sarcoma treatments and nucleotides at ASCO
BioCentury | Jan 17, 2018
Distillery Therapeutics

Cancer

BioCentury | Feb 3, 2017
Company News

Therapeia, Telix deal

BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Solute carrier family 7 member 5 (SLC7A5; LAT1)

Items per page:
1 - 6 of 6